Connect with us

Hi, what are you looking for?

Tuesday, Aug 16, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Numinus submits novel psilocybe formulation for clinical trial

If approved, it will mark the firm’s first independent clinical trial with a proprietary extract

Numinus submits novel psilocybe formulation for clinical trial
Psilocybe cubensis mushrooms. Image via Numinus

Psychedelics firm Numinus Wellness Inc. is advancing its first proprietary psilocybin-based formulation to the clinical trial process.

In a statement Friday, the company said it submitted a clinical trial application to Health Canada for its Phase 1 study, dubbed Hope, on a “naturally derived psilocybe extract formulation,” NBIO-01.

The proprietary formulation is the first to be developed with extracts generated using Numinus’s patent-pending technology, for which a patent was submitted to the US Patent and Trade Office last year.

The company says the formulation has been developed to stably deliver psilocybin with other synergistic compounds, and will be studied for safety and bioavailability.

If approved, it will mark Numinus’s first independent clinical trial, which will be a two-phase study at its clinic in Vancouver. The firm says it will begin testing the extract in 20 healthy volunteers, followed by testing against a psilocybin comparator in another 28 healthy volunteers.

Read more: Numinus to test natural psilocybin safety in Phase 1 trial

Read more: Numinus develops in-house tests to detect compounds in psychedelic mushrooms

“This application significantly advances our product development pipeline, which is aimed at broadening access to safe and effective products for psychedelic-assisted therapies,” says Sharan Sidhu, science officer and general manager of Numinus’s Bioscience division.

“The trial will assess safety and bioavailability and be a stepping stone to the next stage for our IP development,” she says.” This natural product has been developed to be shelf stable, minimally variable and consistently meet label claims.”

The firm said it was starting a Phase 1 clinical trial last year to test the safety of natural psilocybin last year, but a spokesperson tells Mugglehead that NBIO-01 is replacing the natural psilocybin originally planned for that trial.

On Jan. 1, Canada’s Special Access Program was amended, allowing patients with severe health conditions to access psilocybin and other restricted substances. Numinus, which has special licensing to legally produce psilocybin, is listed as a supplier for the program.

Company stock was flat on Friday at $0.70 on the Toronto Stock Exchange.

Read more: What amendments to Canada’s restricted drug program mean for patients and practitioners

Read more: Numinus ends fiscal year with revenue up 72% to $1.5M, losses of $19M

Update (2022-1-27 4:40 p.m. PT): This article has been updated with information that NBIO-01 is replacing natural psilocybin for a previously announced clinical trial.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


B.C. Mental health care company develops passion inspired by Utah pioneers


As rates of mental health disorders increase the demand for psychedelic treatments do too


Series of concerts across the U.S. and Canada will explore music’s role in psychedelic-assisted therapy


Numinus' gross margin improved to 29.1 per cent during Q2 2022 following acquisitions of Mindspace Psychology Services Inc. and the Neurology Centre of Toronto